200 jednostek
Sponsors
Merz Pharmaceuticals GmbH
Conditions
Lower limb spasticityPediatric lower limb (LL) spasticity (SP) caused by cerebral palsy (CP)
Phase 3
A prospective, randomized, double-blind, placebo-controlled, two-stage, multicenter study with an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of lower limb spasticity in children and adolescents with cerebral palsy
CompletedCTIS2023-503420-19-00
Start: 2022-10-12End: 2025-03-04Target: 25Updated: 2024-12-20
Prospective, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of NT 201 in the treatment of lower limb spasticity caused by stroke or traumatic brain injury in adult subjects, followed by an open label extension with or without combined upper limb treatment
Active, not recruitingCTIS2023-505810-12-00
Start: 2019-09-03Target: 343Updated: 2025-10-29